We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioNTech (BNTX) Up More Than 100% So Far This Year: Here's Why
Read MoreHide Full Article
Shares of BioNTech SE (BNTX - Free Report) have risen sharply in the year so far. The stock has skyrocketed 138.6% against the industry’s decrease of 5.7%.
BioNTech has been riding high on the success of the two-shot COVID-19 vaccine, BNT162b2/Comirnaty, which it has developed in partnership with Pfizer (PFE - Free Report) . The company has made rapid progress with the vaccine, which has been developed in record time and is now approved for emergency/temporary use in individuals 16 years of age and older in 91 countries worldwide. Global vaccinations are in full swing.
As of May 3, 2021, Pfizer/BioNTech had shipped approximately 430 million doses of BNT162b2 to 91 countries, bringing in significant revenues for both companies. Moreover, Pfizer/BioNTech have signed agreements to deliver over 1.8 billion doses of BNT162b2 in 2021.
Earlier this month, the FDA expanded BNT162b2’s Emergency Use Authorization to allow vaccinating adolescents aged 12-15 years old.
Studies are also ongoing to expand the authorization of BNT162b2 to additional population groups, such as children from six months to 11 years of age. The companies are also evaluating the administration of a single booster dose five to seven months after receiving the second dose of BNT162b2, mainly with the aim of protection against the emerging variants of concern. Successful development of the same will be a major boost for the company.
Earlier this week, the European Medicines Agency approved a change to the existing storage conditions for Comirnaty. The thawed, undiluted COVID-19 vaccine can now be stored at fridge temperatures of 2°C - 8°C for a period of 31 days, instead of five days at fridge temperatures as previously prescribed.
BioNTech/Pfizer have already submitted a similar request to the FDA and plan to request additional amendments with other regulatory authorities worldwide. This can be a major storage and logistical advantage for the companies over its peers.
Other marketed COVID-19 vaccines are Moderna’s (MRNA - Free Report) mRNA-1273, J&J’s single-shot COVID-19 vaccine and AstraZeneca’s (AZN - Free Report) COVID-19 vaccine.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
BioNTech (BNTX) Up More Than 100% So Far This Year: Here's Why
Shares of BioNTech SE (BNTX - Free Report) have risen sharply in the year so far. The stock has skyrocketed 138.6% against the industry’s decrease of 5.7%.
BioNTech has been riding high on the success of the two-shot COVID-19 vaccine, BNT162b2/Comirnaty, which it has developed in partnership with Pfizer (PFE - Free Report) . The company has made rapid progress with the vaccine, which has been developed in record time and is now approved for emergency/temporary use in individuals 16 years of age and older in 91 countries worldwide. Global vaccinations are in full swing.
As of May 3, 2021, Pfizer/BioNTech had shipped approximately 430 million doses of BNT162b2 to 91 countries, bringing in significant revenues for both companies. Moreover, Pfizer/BioNTech have signed agreements to deliver over 1.8 billion doses of BNT162b2 in 2021.
Earlier this month, the FDA expanded BNT162b2’s Emergency Use Authorization to allow vaccinating adolescents aged 12-15 years old.
Studies are also ongoing to expand the authorization of BNT162b2 to additional population groups, such as children from six months to 11 years of age. The companies are also evaluating the administration of a single booster dose five to seven months after receiving the second dose of BNT162b2, mainly with the aim of protection against the emerging variants of concern. Successful development of the same will be a major boost for the company.
Earlier this week, the European Medicines Agency approved a change to the existing storage conditions for Comirnaty. The thawed, undiluted COVID-19 vaccine can now be stored at fridge temperatures of 2°C - 8°C for a period of 31 days, instead of five days at fridge temperatures as previously prescribed.
BioNTech/Pfizer have already submitted a similar request to the FDA and plan to request additional amendments with other regulatory authorities worldwide. This can be a major storage and logistical advantage for the companies over its peers.
Other marketed COVID-19 vaccines are Moderna’s (MRNA - Free Report) mRNA-1273, J&J’s single-shot COVID-19 vaccine and AstraZeneca’s (AZN - Free Report) COVID-19 vaccine.
BioNTech SE Sponsored ADR Price
BioNTech SE Sponsored ADR price | BioNTech SE Sponsored ADR Quote
Zacks Rank
BioNTech currently has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>